{"id":2970,"date":"2018-04-26T05:00:00","date_gmt":"2018-04-26T05:00:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-perfusion-ab-publ-interim-report-january-march-2018\/"},"modified":"2018-04-26T05:00:00","modified_gmt":"2018-04-26T05:00:00","slug":"xvivo-perfusion-ab-publ-interim-report-january-march-2018","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-march-2018\/","title":{"rendered":"XVIVO Perfusion AB (publ) Interim Report January \u2013 March 2018"},"content":{"rendered":"
SALES RECORD FOR THE QUARTER AND GOOD EBITDA<\/strong><\/div>\n

FIRST QUARTER 2018 (JAN – MAR)<\/span><\/p>\n

\u2022 Net sales of non-durable goods in the quarter amounted to SEK 37.9 (33.6) million, corresponding to an increase of 13 percent in SEK. Sales of non-durable goods increased by 17 percent in local currency. Net sales in the quarter amounted to SEK 42.5 (37.5) million, corresponding to an increase of 13 percent. The increase corresponds to 18 percent in local currency.
<\/span>\u2022 Operating income before depreciation and amortization (EBITDA) amounted to SEK 7.2 million, corresponding to an EBITDA margin of 17 percent. In comparison the operating income before depreciation and amortization (EBITDA) for the first quarter 2017, excluding items affecting comparability, amounted to SEK 5.0 million, corresponding to an EBITDA margin, excluding items affecting comparability, of 13 percent.
\u2022 Operating income amounted to SEK 3.1 (0.0) million, after amortization and depreciation of SEK 4.0 (3.7) million.
\u2022 Net income amounted to SEK 3.8 (0.0) million, resulting in earnings per share of SEK 0.15 (0.0).
\u2022 Cash flow from operating activities was SEK 9.2 (-2.0) million.
\u2022 Sales from warm perfusion (STEEN Solution\u2122 and products and services related to the use of XPS\u2122 or LS\u2122) represented 35 percent (36) of sales of non durable goods.
\u2022 Reimbursement codes (so called CPT codes) have been valid in the USA since 1 January, 2018. The new codes simplify the reimbursement process for hospitals on the American market.
\u2022 2 XPS\u2122 was delivered during the quarter. At the end of the quarter 47 hospitals had access to either XPS\u2122 or LS\u2122.<\/p>\n

CONFERENCE CALL<\/span><\/p>\n

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Monday, February 12, 2018. Telephone UK: +44 (0) 203 139 4830 or USA: +1 718 873 9077, enter code 17299565#.<\/span>\u00a0<\/span><\/p>\n

April 26, 2018
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO<\/span>\u00a0<\/p>\n

\n

For further information please contact:<\/span><\/p>\n

Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com<\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/span><\/p>\n

This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation.\u00a0\u00a0The information was submitted for publication, through the agency of the contact person set out above, at 07:00 am CET on April 26, 2018.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SALES RECORD FOR THE QUARTER AND GOOD EBITDA FIRST QUARTER 2018 (JAN – MAR) \u2022 Net sales of non-durable goods…<\/p>\n","protected":false},"template":"","class_list":["post-2970","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q1","mfn-news-tag-mfn"],"acf":[],"yoast_head":"\nXVIVO Perfusion AB (publ) Interim Report January \u2013 March 2018 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-march-2018\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO Perfusion AB (publ) Interim Report January \u2013 March 2018 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"SALES RECORD FOR THE QUARTER AND GOOD EBITDA FIRST QUARTER 2018 (JAN – MAR) \u2022 Net sales of non-durable goods...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-march-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-interim-report-january-march-2018\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-interim-report-january-march-2018\\\/\",\"name\":\"XVIVO Perfusion AB (publ) Interim Report January \u2013 March 2018 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2018-04-26T05:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-interim-report-january-march-2018\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-interim-report-january-march-2018\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-interim-report-january-march-2018\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO Perfusion AB (publ) Interim Report January \u2013 March 2018\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO Perfusion AB (publ) Interim Report January \u2013 March 2018 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-march-2018\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO Perfusion AB (publ) Interim Report January \u2013 March 2018 - XVIVO","og_description":"SALES RECORD FOR THE QUARTER AND GOOD EBITDA FIRST QUARTER 2018 (JAN – MAR) \u2022 Net sales of non-durable goods...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-march-2018\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-march-2018\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-march-2018\/","name":"XVIVO Perfusion AB (publ) Interim Report January \u2013 March 2018 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2018-04-26T05:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-march-2018\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-march-2018\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-interim-report-january-march-2018\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO Perfusion AB (publ) Interim Report January \u2013 March 2018"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2970","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2970"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}